Ott P, Eldrup E, Oxholm P, Vestergård A, Knudsen J B
Acta Med Scand. 1986;219(3):295-300. doi: 10.1111/j.0954-6820.1986.tb03314.x.
One hundred and eight patients with phlebographically verified deep venous thrombosis were treated with streptokinase. Total or partial thrombolysis was phlebographically demonstrated in 60 patients (55.6%). Three patients died during treatment, all from pulmonary embolism. Six patients developed clinical signs suggestive of pulmonary embolism. In 16 patients (14.8%), major bleeding complicated the treatment. One patient had anaphylactic shock, while various allergic reactions were recorded in 22. Streptokinase therapy in the routine management of deep venous thrombosis carries an acceptable efficacy and safety similar to what has been achieved under research conditions.
108例经静脉造影证实为深静脉血栓形成的患者接受了链激酶治疗。静脉造影显示60例患者（55.6%）实现了完全或部分溶栓。3例患者在治疗期间死亡，均死于肺栓塞。6例患者出现提示肺栓塞的临床症状。16例患者（14.8%）治疗时出现严重出血并发症。1例患者发生过敏性休克，22例记录有各种过敏反应。在深静脉血栓形成的常规治疗中，链激酶治疗具有可接受的疗效和安全性，与研究条件下所取得的结果相似。
